Interleukin-6 -634 C/G and -174 G/C polymorphisms in Korean patients undergoing hemodialysis

Korean Journal of Internal Medicine

Volumn 27, Issue 3, 2012, Pages 327-337

  Ryu, Jung Hwa ^a   Kim, Seung Jung ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Hemodialysis; Inflammation; Interleukin 6 polymorphism; Vascular access failure

Indexed keywords

ALBUMIN; CREATININE; CYTOSINE; GENOMIC DNA; GUANINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INTERLEUKIN GENE; KIDNEY FAILURE; KOREA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTHESIS FAILURE; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; VASCULAR ACCESS; VASCULAR PATENCY;

ADULT; AGED; ARTERIOVENOUS SHUNT, SURGICAL; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT OCCLUSION, VASCULAR; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RENAL DIALYSIS; REPUBLIC OF KOREA; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84867043973     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.3.327     Document Type: Article

References (36)

1. De Marchi S, Falleti E, Giacomello R, et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 1996;7:1169-1177.
2. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
3. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476.
4. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001;12:1549-1557.
5. Stenvinkel P, Pecoits-Filho R, Lindholm B; for the Dial-Gene Consortium. Gene polymorphism association studies in dialysis: the nutrition-inf lammation axis. Semin Dial 2005;18:322-330.
6. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004;8:118-129.
7. Rao M, Wong C, Kanetsky P, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 2007;72:549-556.
8. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005;45:324-333.
9. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene-174G>C and-572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001;21:1458-1463.
10. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003;64:616-622.
11. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992;187:584-589.
12. Ikeda U, Ikeda M, Oohara T, et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991;260(5 Pt 2):H1713-H1717.
13. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993;70:138-143.
14. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376.
15. Hulkkonen J, Pertovaara M, A ntonen J, Pasternack A, Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL-6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 2001;40:656-661.
16. Aker S, Bantis C, Reis P, et al. Inf luence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol Dial Transplant 2009;24:2847-2851.
17. Kitamura A, Hasegawa G, Obayashi H, et al. Interleukin-6 polymorphism (-634 C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002;19:1000-1005.
18. Nakajima T, Ota N, Yoshida H, Watanabe S, Suzuki T, Emi M. Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun 1999;1:115-119.
19. Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res 2007;150:101-105.
20. Chang CJ, Ko YS, Ko PJ, et al. Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int 2005;68:1312-1319.
21. Liu BC, Li L, Gao M, Wang YL, Yu JR. Microinflammation is involved in the dysfunction of arteriovenous fistula in patients with maintenance hemodialysis. Chin Med J (Engl) 2008;121:2157-2161.
22. Marrone D, Pertosa G, Simone S, et al. Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis 2007;49:664-673.
23. Zhai R, Liu G, Yang C, Huang C, Wu C, Christiani DC. The G to C polymorphism at-174 of the interleukin-6 gene is rare in a Southern Chinese population. Pharmacogenetics 2001;11:699-701.
24. Zheng C, Huang DR, Bergenbrant S, et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000;109:39-45.
25. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001;22:2243-2252.
26. Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001;72:720-726.
27. Lim CS, Zheng S, Kim YS, et al. The-174 G to C polymorphism of interleukin-6 gene is very rare in Koreans. Cytokine 2002;19:52-54.
28. Burzotta F, Iacoviello L, Di Castelnuovo A, et al. Relation of the-174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001;88:1125-1128.
29. Bennet AM, Prince JA, Fei GZ, et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis 2003;171:359-367.
30. Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000;85:1334-1339.
31. Mittal RD, Manchanda PK. Association of interleukin (IL)-4 intron-3 and IL-6-174 G/C gene polymorphism w ith susceptibility to end-stage renal disease. Immunogenetics 2007;59:159-165.
32. Brull DJ, Leeson CP, Montgomery HE, et al. The effect of the Interleukin-6-174 G > C promoter gene polymorphism on endothelial function in healthy volunteers. Eur J Clin Invest 2002;32:153-157.
33. Stoica AL, Stoica E, Constantinescu I, Uscatescu V, Ginghina C. Interleukin-6 and interleukin-10 gene polymorphism, endothelial dysf unction, and postoperative prognosis in patients with peripheral arterial disease. J Vasc Surg 2010;52:103-109.
34. Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 2005;10:191-198.
35. Libra M, Signorelli SS, Bevelacqua Y, et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006;59:211-215.
36. Kiszel P, Mako V, Prohaszka Z, Cervenak L. Interleukin-6-174 promoter polymorphism does not influence IL-6 production after LPS and IL-1 beta stimulation in human umbilical cord vein endothelial cells. Cytokine 2007;40:17-22.